CA Patent

CA2593582A1 — Bendamustine pharmaceutical compositions

Assigned to Cephalon LLC · Expires 2006-07-20 · 20y expired

What this patent protects

The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensit…

USPTO Abstract

The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases. Preferred solvent used in a pre-lyophilized composition of bendamustine is tertiary-butyl alcohol .

Drugs covered by this patent

Patent Metadata

Patent number
CA2593582A1
Jurisdiction
CA
Classification
Expires
2006-07-20
Drug substance claim
No
Drug product claim
No
Assignee
Cephalon LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.